Literature DB >> 29368033

Development and performance of npde for the evaluation of time-to-event models.

M Cerou1,2,3,4,5, M Lavielle6, K Brendel7, M Chenel7, E Comets8,9,10,11.   

Abstract

PURPOSE: Normalised prediction distribution errors (npde) are used to graphically and statistically evaluate mixed-effect models for continuous responses. In this study, our aim was to extend npde to time-to-event (TTE) models and evaluate their performance.
METHODS: Let V denote a dataset with censored TTE observations. The null hypothesis (H0) is that observations in V can be described by model M. We extended npde to TTE models using imputations to take into account censoring. We then evaluated their performance in terms of type I error and power to detect model misspecifications for TTE data by means of a simulation study with different sample sizes.
RESULTS: Type I error was found to be close to the expected 5% significance level for all sample sizes tested. The npde were able to detect misspecifications in the baseline hazard as well as in the link between the longitudinal variable and the survival function. The ability to detect model misspecifications increased as the difference in the shape of the survival function became more apparent. As expected, the power also increased as the sample size increased. Imputing the censored events tended to decrease the percentage of rejections.
CONCLUSIONS: We have shown that npde can be readily extended to TTE data and that they perform well with an adequate type I error.

Keywords:  PSA; model evaluation; npde; time-to-event

Mesh:

Substances:

Year:  2018        PMID: 29368033     DOI: 10.1007/s11095-017-2291-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Survival analysis.

Authors:  Robert Flynn
Journal:  J Clin Nurs       Date:  2012-08-04       Impact factor: 3.036

2.  Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.

Authors:  Thi Huyen Tram Nguyen; Emmanuelle Comets; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-11       Impact factor: 2.745

Review 3.  Basic concepts and methods for joint models of longitudinal and survival data.

Authors:  Joseph G Ibrahim; Haitao Chu; Liddy M Chen
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

4.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Authors:  Ian F Tannock; Karim Fizazi; Sergey Ivanov; Camilla Thellenberg Karlsson; Aude Fléchon; Iwona Skoneczna; Francisco Orlandi; Gwenaelle Gravis; Vsevolod Matveev; Sevil Bavbek; Thierry Gil; Luciano Viana; Osvaldo Arén; Oleg Karyakin; Tony Elliott; Alison Birtle; Emmanuelle Magherini; Laurence Hatteville; Daniel Petrylak; Bertrand Tombal; Mark Rosenthal
Journal:  Lancet Oncol       Date:  2013-06-04       Impact factor: 41.316

5.  Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.

Authors:  Solène Desmée; France Mentré; Christine Veyrat-Follet; Jérémie Guedj
Journal:  AAPS J       Date:  2015-03-05       Impact factor: 4.009

6.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

Review 7.  Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group.

Authors:  A Lawrence Gould; Mark Ernest Boye; Michael J Crowther; Joseph G Ibrahim; George Quartey; Sandrine Micallef; Frederic Y Bois
Journal:  Stat Med       Date:  2014-03-14       Impact factor: 2.373

8.  Basic concepts in population modeling, simulation, and model-based drug development.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

9.  A time to event tutorial for pharmacometricians.

Authors:  Nick Holford
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-05-15

10.  Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.

Authors:  Jorie Versmissen; Daniëlla M Oosterveer; Mojgan Yazdanpanah; Joep C Defesche; Dick C G Basart; Anho H Liem; Jan Heeringa; Jacqueline C Witteman; Peter J Lansberg; John J P Kastelein; Eric J G Sijbrands
Journal:  BMJ       Date:  2008-11-11
View more
  1 in total

1.  Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.

Authors:  Hoai-Thu Thai; Nadia Gaudel; Marc Cerou; Geraldine Ayral; Jean-Baptiste Fau; Bernard Sebastien; Helgi van de Velde; Dorothée Semiond; Christine Veyrat-Follet
Journal:  Br J Clin Pharmacol       Date:  2021-11-26       Impact factor: 3.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.